10-Q: PowerUp Acquisition Corp. Reports Third Quarter 2024 Results Amidst Merger Pursuit

PowerUp Acquisition Corp. reported a net loss for the third quarter of 2024 and is actively pursuing a business combination with Aspire Biopharma after terminating a previous merger agreement.

Summary

• PowerUp Acquisition Corp. reported a net loss of $537,019 for the three months ended September 30, 2024, and a net loss of $3,606,378 for the nine months ended September 30, 2024.
• The company's operating expenses were $630,772 for the quarter and $3,654,462 for the nine-month period.
• Interest income from the trust account was $76,746 for the quarter and $481,511 for the nine-month period.
• The company terminated its merger agreement with Visiox Pharmaceuticals in July 2024.
• PowerUp entered into a new merger agreement with Aspire Biopharma in August 2024, which is intended to serve as the company's initial business combination.
• As of September 30, 2024, the company had $6,601,357 in its trust account and a working capital deficit of $6,511,072.
• The company has until February 17, 2025, to complete a business combination.
• The company has identified a material weakness in its internal controls over debt discount, amortization and debt in financial reporting.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the net losses, working capital deficit, terminated merger agreement, and the identified material weakness in internal controls. However, the company is actively pursuing a new merger, which provides some hope for the future.

Positives

• The company is actively pursuing a business combination with Aspire Biopharma.
• The company has $6,601,357 in its trust account to fund a business combination.

Negatives

• The company reported a net loss of $537,019 for the third quarter of 2024.
• The company has a working capital deficit of $6,511,072.
• The company terminated its merger agreement with Visiox Pharmaceuticals.
• The company has identified a material weakness in its internal controls over debt discount, amortization and debt in financial reporting.
• The company's remaining life as of September 30, 2024 is under 12 months.

Risks

• The company may not be able to complete a business combination by February 17, 2025.
• The company may need to raise additional capital through loans or investments.
• The company's ability to continue as a going concern is in doubt.
• The company has identified a material weakness in its internal controls over financial reporting.
• The company may not be able to obtain additional financing on commercially acceptable terms.

Future Outlook

The company is focused on completing its business combination with Aspire Biopharma by February 17, 2025, and may need to raise additional capital to do so.

Management Comments

• The company's management is focused on completing a business combination.
• The company's management is aware of the material weakness in internal controls and is working to address it.

Industry Context

The document reflects the typical challenges faced by SPACs, including the need to secure a suitable merger target within a limited timeframe and the potential for redemptions to impact available capital. The termination of the Visiox merger and the subsequent agreement with Aspire highlight the dynamic nature of SPAC transactions.

Comparison to Industry Standards

• The financial results are typical for a SPAC in its pre-merger phase, with minimal operating revenue and reliance on interest income from the trust account.
• The net losses are expected as the company incurs costs related to the search for a business combination.
• The working capital deficit is a common issue for SPACs, as they typically do not generate revenue until after a merger.
• The material weakness in internal controls is a concern and needs to be addressed to ensure accurate financial reporting.
• The company's timeline to complete a business combination is consistent with industry standards for SPACs.

Management Changes

Related Party Transactions

• The company has related party loans with the New Sponsor and its affiliates.
• The company pays an administrative services fee to an affiliate of the New Sponsor.
• The New Sponsor purchased shares and warrants from the Original Sponsor.

Stakeholder Impact

• Shareholders are impacted by the net losses and the uncertainty surrounding the business combination.
• Employees are impacted by the company's financial situation and the potential for changes in the future.
• Creditors are impacted by the company's working capital deficit and the potential need for additional financing.

Next Steps

• The company will continue to pursue its business combination with Aspire Biopharma.
• The company will work to address the material weakness in its internal controls.
• The company may seek additional financing to support its operations and business combination efforts.

Key Dates

Keywords

Business Combination, Merger, SPAC, Acquisition, Trust Account, Net Loss, Aspire Biopharma, Visiox Pharmaceuticals, Financial Reporting, Internal Controls